Früh, Martin

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2017

2017

Peters, Solange; Gettinger, Scott; Johnson, Melissa L; Jänne, Pasi A; Garassino, Marina C; Christoph, Daniel; Toh, Chee Keong; Rizvi, Naiyer A; Chaft, Jamie E; Carcereny Costa, Enric; Patel, Jyoti D; Chow, Laura Q M; Koczywas, Marianna; Ho, Cheryl; Früh, Martin; van den Heuvel, Michel; Rothenstein, Jeffrey; Reck, Martin; Paz-Ares, Luis; Shepherd, Frances A; ... (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of clinical oncology, 35(24), pp. 2781-2789. American Society of Clinical Oncology 10.1200/JCO.2016.71.9476

Delaunay, Myriam; Cadranel, Jacques; Lusque, Amélie; Meyer, Nicolas; Gounant, Valérie; Moro-Sibilot, Denis; Michot, Jean-Marie; Raimbourg, Judith; Girard, Nicolas; Guisier, Florian; Planchard, David; Metivier, Anne-Cécile; Tomasini, Pascale; Dansin, Eric; Pérol, Maurice; Campana, Marion; Gautschi, Oliver; Früh, Martin; Fumet, Jean-David; Audigier-Valette, Clarisse; ... (2017). Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European respiratory journal, 50(2) European Respiratory Society 10.1183/13993003.00050-2017

Baty, Florent; Joerger, Markus; Früh, Martin; Klingbiel, Dirk; Zappa, Francesco; Brutsche, Martin (2017). 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. Journal of translational medicine, 15(1), p. 66. BioMed Central 10.1186/s12967-017-1174-z

Provide Feedback